PS
VIR icon

Principal Securities’s Vir Biotechnology VIR Stock Holding History

Principal Securities’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$117 – 3891
2025
Q1 		$117 Hold
16
– – ﹤0.01% 3501
2024
Q4 		$117 Buy
+16
New +$126 ﹤0.01% 3496
2024
Q3 		– Sell
-33
Closed -$294 – 3549
2024
Q2 		$294 Buy
+33
New +$316 ﹤0.01% 3268

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's VIR Position: Q2 2025 in Review

Principal Securities sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 16 shares — an estimated $117 sold.

Principal Securities first reported a position in VIR in Q2 2024 and held it in 3 quarters. The position peaked at $294 in Q2 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Principal Securities reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 16 Vir Biotechnology shares in Q2 2025, an estimated $117.
  • Principal Securities first reported a position in Vir Biotechnology in Q2 2024 and held it in 3 quarters.
  • Principal Securities's Vir Biotechnology position peaked at $294 in Q2 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.